ArticleCellular and molecular life sciences : CMLS2025
Dapagliflozin alleviates mitochondrial damage in the myocardium under diabetic conditions by targeting sortilin.
Article in Cellular and molecular life sciences : CMLS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MicroRNAs in Heart Failure Pathogenesis and Progression: Mechanistic Control, Biomarker Potential, and Translational Perspectives.Life (Basel, Switzerland) · 2026Review
- Direct dapagliflozin exposure enhances respiration and membrane hyperpolarization in isolated cardiac mitochondria.Frontiers in physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundType 2 diabetes patients are particularly vulnerable to myocardial injury, including mitochondrial damage in the myocardium. This study aims to evaluate the therapeutic potential and mechanisms of dapagliflozin in mitigating myocardial mitochondrial injury under diabetic conditions.
methodsA cell model was established using a high-glucose, high-fat combination. Dapagliflozin was dissolved in Dimethyl sulfoxide (DMSO) and added to the culture medium. A type 2 diabetic mouse model was induced by high-fat feeding combined with Streptozotocin (STZ) injection, with dapagliflozin administered via oral gavage. SORT1 was silenced using siRNA. Phenotypic evaluation and mechanistic analysis were performed through qPCR, Western blot (WB), activity assays, Reactive Oxygen Species (ROS) measurement, transmission electron microscopy, and Masson's staining.
resultsIn vitro studies, we demonstrated that under diabetic conditions, mitochondrial damage was evident, characterized by a decrease in mitochondrial respiratory chain complex content, reduced complex activity, increased ROS levels, and structural damage to mitochondria. Silencing SORT1 resulted in a similar mitochondrial phenotype under diabetic conditions, highlighting the critical role of sortilin in mitochondrial function. Addition of dapagliflozin to the culture medium significantly improved mitochondrial dysfunction caused by high glucose and high fat, a finding also confirmed in the mouse model. Moreover, dapagliflozin alleviated myocardial fibrosis induced by diabetes in the mouse model.
conclusionsOur findings uncover a novel molecular mechanism through which dapagliflozin improves myocardial mitochondrial injury under diabetic conditions, suggesting SORT1 as a potential therapeutic target for treating myocardial injury in diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.